Ocean Biomedical congratulates its JV partner Virion Therapeutics, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker oral presentation highlighting the first-ever human data from its novel checkpoint modifier immunotherapy for HBV functional cure, at the 33rd Annual Meeting of APASL, taking place in Kyoto, Japan from March 27 – 31. The late breaker Phase 1 data presented, Virion APASL 2024 Clinical Late Breaker , which includes Virion’s first checkpoint modifier, glycoprotein D, demonstrated that VRON-0200 was safe and well tolerated, with no clinical or laboratory changes of concern, following a single intramuscular of 10 chronically HBV-infected patients, representing 641 patient safety days. “These first ever data for a checkpoint modifier containing T cell vaccine of any kind, represent a critical first step towards our goal of bringing a safe, well tolerated, and easy to administer interferon-sparing immunotherapy to HBV-infected patients worldwide,” said Virion’s CEO, Dr. Andrew Luber. Luber added, “VRON-0200 is our lead clinical program and these clinical safety data will further support our proprietary platform technologies and other pipeline programs in development, including VRON-0300, which is for patients with advanced solid tumors.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCEA:
- Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
- Largest borrow rate increases among liquid names
- Ocean Biomedical Inc options imply 17.8% move in share price post-earnings
- Ocean Biomedical Inc options imply 14.5% move in share price post-earnings
- Ocean Biomedical Inc options imply 31.8% move in share price post-earnings